Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 8/20 | 0.43 |
| ▸ | CDK8 | P49336 | 8/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369320 | 0.85 | MLYCD (0.43) | USP30MKNK1MKNK2CHEK1MLYCD | |
| SCHEMBL14906657 | 0.81 | FGFR2 (0.52) | MKNK1MKNK2 | |
| SCHEMBL29869630 | 0.81 | FGFR2 (0.52) | MKNK1MKNK2 | |
| SCHEMBL13984679 | 0.79 | MKNK1 (0.57) | USP30MKNK1MKNK2CHEK1MAP4K4 | |
| SCHEMBL19663215 | 0.77 | MKNK1 (0.61) | MKNK1MKNK2GPR119CHEK1MAP4K4 | |
| SCHEMBL1222255 | 0.77 | CHEK1 (0.70) | MKNK1MKNK2CHEK1MAP4K4ESR1 | |
| SCHEMBL19662826 | 0.77 | MKNK1 (0.61) | MKNK1MKNK2CHEK1MAP4K4ESR1 | |
| SCHEMBL21400335 | 0.75 | MKNK1 (0.60) | MKNK1MKNK2CHEK1MAP4K4ESR1 | |
| SCHEMBL9152657 | 0.75 | MLYCD (0.53) | MLYCD | |
| SCHEMBL4449884 | 0.75 | MAPT (0.56) | MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| CN-109476663-B | Pyrazolopyridine derivatives for the treatment of cancer | 基因泰克公司 | 2021-11-09 | — | — | CN | disclosed |
| EP-3464286-B1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| EP-3464286-A1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017205538-A1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205538-A1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247989-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, CREBBP | USP30 1829/4885MKNK1 1568/4885MKNK2 705/4885 |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | USP30 1829/4885MKNK1 1568/4885MKNK2 705/4885 |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | USP30 1829/4885MKNK1 1568/4885MKNK2 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.